Suchergebnisse - "Touzeau, Cyrille"

PubPharm (208)

1

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

enthalten in: Blood | 2024

von Durand, R. | Descamps, G. | Bellanger, C. | +17

CommentIn: Blood. 2024 Mar 28;143(13):1202-1204. - PMID 38546638

2

Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications

enthalten in: Blood advances | 2024

von Letouzé, E. | Moreau, P. | Munshi, N. | +3

3

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies : a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myélome

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2024

von Jourdes, A. | Cellerin, E. | Touzeau, C. | +31

4

Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma

enthalten in: Blood | 2024

von Touzeau, C. | Perrot, A. | Hulin, C. | +13

5

Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access : The CARMYN study

enthalten in: EJHaem | 2024

von Laribi, K. | Leleu, X. | Texier, N. | +16

6

Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide

enthalten in: American journal of hematology | 2024

von Jullien, M. | Guillaume, T. | Le Bourgeois, A. | +19

7

Venous thromboembolism prophylaxis and multiple myeloma patients in real-life : Results of a large survey and clinical guidance recommendations from the IFM group

enthalten in: Thrombosis research | 2024

von Frenzel, L. | Decaux, O. | Macro, M. | +10

8

Quad-class exposed/refractory myeloma is associated with short survival

enthalten in: British journal of haematology | 2024

von Piron, B. | Costes-Tertrais, D. | Gastinne, T. | +6

9

Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen

enthalten in: Haematologica | 2024

von Piron, B. | Bastien, M. | Antier, C. | +9

10

Author Correction : Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation

enthalten in: Nature cancer | 2023

von Derrien, J. | Gastineau, S. | Frigout, A. | +11

ErratumFor: Nat Cancer. 2023 Nov;4(11):1536-1543. - PMID 37653140

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]